Physician profile
Thomas Henry
NPI 1306451067
$956.08
in general payments reported to CMS, 2019-2025
13 companies · $654 in 2025
The $654 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2023: $28.10 · 2024: $150 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819 · Travel and Lodging: $12.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.22 |
| Travel and Lodging | $12.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $211.13 | 2024-2025 | Lifevest |
| Abbott Laboratories | $152.23 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.78 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $87.15 | 2024-2025 | Verquvo |
| Pfizer INC. | $72.64 | 2025 | |
| Abiomed | $67.54 | 2024 | |
| Boston Scientific Corporation | $65.45 | 2025 | Watchman Flx, Bodyguardian, General - Therapies |
| Scpharmaceuticals INC. | $44.48 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $36.10 | 2025 | Farxiga |
| Novo Nordisk INC | $30.05 | 2025 | Ozempic |
| Amgen INC. | $19.83 | 2025 | Repatha |
| Lilly USA, LLC | $19.33 | 2025 | Zepbound |
| Medtronic, INC. | $13.37 | 2024 | Linq II |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.